+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 1
Phase 2
Age: 18Years +
All Genders
ID06821503

Phase IbII Study of LM-108 with Penpulimab Plus Chemotherapy for Treating Advanced Solid Tumors and Pancreatic Cancer

Led by Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Updated on 2026-03-10

72

Participants Needed

16

Research Sites

52 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating the preliminary efficacy, safety, and tolerability of LM-108 combined with anti-tumor therapies in patients with advanced solid tumors, focusing particularly on advanced pancreatic cancer. This open-label, multicenter Phase IbII clinical study aims to determine appropriate dosing and assess treatment effects in this patient population. The study is sponsored by Chia Tai Tianqing Pharmaceutical Group Co., Ltd and involves patients who have not received prior systemic treatment for unresectable locally advanced or metastatic pancreatic cancer. The trial includes two treatment groups one receiving LM-108 injection combined with penpulimab injection, albumin-bound paclitaxel, and gemcitabine, and the other receiving LM-108 with albumin-bound paclitaxel and gemcitabine. Treatments are given in cycles of 28 days. The Phase Ib portion establishes the recommended dose of LM-108 with the combination therapies, and Phase II further explores the efficacy and safety of these combinations specifically in advanced pancreatic cancer. Participants will undergo regular assessments including monitoring for dose-limiting toxicities up to 28 days and progression-free survival up to 48 weeks. Additional outcomes such as overall survival, duration of response, and overall response rate will be evaluated up to 96 weeks. The study involves physical fitness evaluations, lesion measurements, and monitoring of organ and bone marrow function, with patient safety and treatment tolerability closely followed throughout the trial period.

CONDITIONS

Brief Title

Clinical Study Evaluating the Safety, Tolerability, and Preliminary Efficacy of LM-108 ± Penpulimab+Chemotherapy in Advanced Solid Tumors - Cohort C

Research Team

L

Lin Shen, Doctor

J

Jihui Hao, Doctor

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here